Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therape reported $67.7M in revenue and a $412.7M net loss for fiscal 2025.
See the full NTLA financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
New non-dilutive term loan with OrbiMed adds near-term cash and potential follow-on funding to support Intellia’s lonvo-z launch, nexiguran program and pipeline.
Intellia Therapeutics (NTLA) entered a non-dilutive senior secured term loan facility of up to $400 million with OrbiMed.
The facility provides $75 million funded at closing and up to $325 million in additional capital. Five milestone-based tranches total up to $225 million, primarily linked to lonvoguran ziclumeran (lonvo-z), with a further $100 million available by mutual agreement during the five-year term. The company said the financing supports a planned U.S. approval and commercial launch of lonvo-z for hereditary angioedema, advancement of nexiguran ziclumeran in transthyretin amyloidosis, and early pipeline development.
Loading...
Loading translation...
Positive
Up to $400 million non-dilutive senior secured term loan facility with OrbiMed
$75 million initial term loan funded at closing, immediately strengthening liquidity
Additional $225 million in five tranches, drawable upon achieving specified milestones
Further $100 million available by mutual agreement during the five-year facility term
Financing supports planned lonvo-z U.S. approval and launch in HAE and nexiguran ziclumeran milestones
Negative
Facility is a senior secured term loan, adding potential debt obligations up to $400 million
Access to $225 million in tranches depends on achieving specified lonvo-z-related milestones
An additional $100 million is available only subject to mutual agreement between Intellia and OrbiMed
News Explained
At June 30, 2026, Intellia reported $628 million of cash and investments—equivalent to 688 days of the last reported operating cash use—so the $75 million funded draw adds to existing liquidity, while the remaining $325 million is conditional on milestones or mutual agreement.
Available liquidity against the last reported quarterly operating outflow, in days at that rate($106,128,000 + $331,631,000 + $190,595,000) / ($83,113,000 / 91) = 688 days
Market Context
NTLA's high short positioning is a platform risk context for evaluating this financing announcement....
Analysis
NTLA's high short positioning is a platform risk context for evaluating this financing announcement. The facility's milestone conditions and recent insider net selling add factors to monitor alongside execution of the company's plans.
Key Figures
Debt facility:$400 millionUpfront funding:$75 millionMilestone-linked funding:$325 million+3 more
6 metrics
Debt facility$400 millionNon-dilutive senior secured term loan facility
Upfront funding$75 millionFunded at closing
Milestone-linked funding$325 millionAdditional funding tied to milestones
Optional tranches$225 millionFive tranches subject to specified milestones
Mutual-agreement funding$100 millionAvailable subject to mutual agreement
Equity awards for six new employees were followed by a negative price reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The stock gained after the positive earnings disclosure but declined after two of three inducement-grant disclosures, showing mixed reactions across recent news.
Key Terms
crispr, non-dilutive, senior secured term loan, form 8-k, +1 more
5 terms
crisprtechnical
"focused on revolutionizing medicine leveraging CRISPR gene editing"
CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.
non-dilutivefinancial
"entered into a $400 million non-dilutive senior secured term loan facility"
Non-dilutive describes funding or income that does not reduce existing shareholders’ ownership percentage. It matters to investors because it lets a company raise money or generate value—through grants, loans, licensing deals, or revenue—without issuing extra shares, so each existing share keeps the same claim on profits and control; think of adding toppings to a cake without cutting it into more slices.
senior secured term loanfinancial
"$400 million non-dilutive senior secured term loan facility with OrbiMed"
A senior secured term loan is a type of borrowing where a company borrows money and promises to pay it back over a fixed period, with the loan secured by the company's assets as collateral. Because it is "senior," it has priority over other debts if the company faces financial trouble, and being "secured" means lenders have a claim on specific assets. For investors, this makes the loan a safer and more predictable investment compared to unsecured or subordinate debts.
form 8-kregulatory
"filed with the Securities and Exchange Commission on a Current Report on Form 8-K"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
haemedical
"patients with hereditary angioedema (HAE)"
Hereditary angioedema (HAE) is a rare genetic disorder that causes sudden, severe swelling in tissues such as the face, throat, abdomen and limbs due to abnormal control of blood vessel leakage. It matters to investors because HAE treatments, which can be life‑saving and are often taken long‑term, represent a specialized drug market with high per‑patient revenue and regulatory, pricing and reimbursement risks similar to other rare‑disease therapies.
$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm. The transaction provides Intellia with greater financial and operational flexibility as it advances toward several key milestones, including a planned U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) as a one-time treatment for patients with hereditary angioedema (HAE).
“Lonvo-z has the potential to transform the treatment paradigm for people living with HAE as well as the future capital needs of our company,” said Edward Dulac, Intellia’s Chief Financial Officer. “This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE, advance nexiguran ziclumeran through multiple important milestones in transthyretin amyloidosis and create value through our early pipeline development efforts.”
“OrbiMed is proud to partner with Intellia Therapeutics, a well-recognized leader in the in vivo gene editing revolution,” said Matthew Rizzo, General Partner at OrbiMed. “We are looking forward to supporting the team as it approaches a number of exciting and transformational milestones.”
The facility includes an initial term loan of $75 million that was funded at closing;5 additional tranches totaling up to $225 million that can be drawn at Intellia’s option subject to its achievement of specified milestones related primarily to lonvo-z;and an additional $100 million available subject to mutual agreement between the parties during the five-year term of the agreement. Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K.
TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia. Covington & Burling LLP acted as legal advisor to OrbiMed.
About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the expected benefits of the senior secured term loan facility, including the extent to which the facility may provide Intellia with financial, operational and strategic flexibility and enable Intellia to execute its plans and advance its programs through anticipated value inflection points; Intellia’s ability to achieve the applicable milestones and satisfy the other conditions required to access the additional $225 million under the facility; the availability of an additional $100 million subject to mutual agreement between the parties; the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (formerly known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of the biologics license application for lonvo-z, its ability to successfully launch lonvo-z in HAE, its belief that lonvo-z has the potential to transform the treatment paradigm for people living with HAE as well as the Company’s future capital needs, lonvo-z’s potential to become the first one-time treatment for HAE, and the potential for lonvo-z to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene following a single dose; its ability to advance nexiguran ziclumeran or "nex-z" (formerly known as NTLA-2001) through multiple important milestones in transthyretin amyloidosis; and its ability to create value through its early pipeline development efforts.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to achieve the applicable milestones and satisfy the other conditions required to access additional tranches under the loan facility; the possibility that Intellia and OrbiMed will not mutually agree to make the additional $100 million available; risks associated with Intellia’s indebtedness, including its debt-service obligations, restrictive covenants, security interests and the potential for default; the possibility that the loan facility will not provide the anticipated financial, operational or strategic flexibility or enable Intellia to execute its plans as expected; uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z and nex-z, including risks related to the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials or regulatory filings due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its recent quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. jason.fredette@intelliatx.com
What financing did Intellia Therapeutics (NTLA) announce with OrbiMed?
Intellia Therapeutics announced a non-dilutive senior secured term loan facility with OrbiMed for up to $400 million. The company describes this as providing greater financial and operational flexibility as it progresses lonvoguran ziclumeran (lonvo-z), nexiguran ziclumeran and its early-stage pipeline.
How much immediate funding does Intellia Therapeutics (NTLA) receive from the OrbiMed loan facility?
Intellia receives an initial term loan of $75 million that was funded at closing. This upfront amount increases the company’s available cash as it advances toward key milestones, including a planned U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema.
How is the remaining $325 million in the OrbiMed facility for Intellia (NTLA) structured?
Beyond the initial $75 million, the facility includes five additional tranches totaling up to $225 million, drawable at Intellia’s option upon meeting specified milestones primarily related to lonvo-z, plus an extra $100 million that is available subject to mutual agreement during the five-year term.
What will Intellia Therapeutics (NTLA) use the OrbiMed financing for?
The company said the non-dilutive financing will support a planned U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, advance nexiguran ziclumeran through important transthyretin amyloidosis milestones, and fund value-creating efforts in its early pipeline.
Is the OrbiMed loan facility dilutive to Intellia Therapeutics (NTLA) shareholders?
The company describes the OrbiMed facility as a non-dilutive senior secured term loan, meaning it does not involve issuing new equity under the disclosed terms. This structure allows Intellia to access up to $400 million in financing without direct share dilution.
Over what period is the OrbiMed loan facility available to Intellia Therapeutics (NTLA)?
The term loan facility has a five-year term. During this period, Intellia can draw up to $225 million in milestone-based tranches and potentially access an additional $100 million by mutual agreement, on top of the $75 million already funded at closing.
Which Intellia drug candidates are highlighted in connection with the OrbiMed financing for NTLA?
The financing is tied primarily to lonvoguran ziclumeran (lonvo-z), including milestones related to its development and planned U.S. approval and launch for hereditary angioedema. It also supports nexiguran ziclumeran milestones in transthyretin amyloidosis and broader early pipeline development.
